Concure Oncology plans to use $2.5 million in new funding to help make its targeted radiation treatment option increasingly available to early-stage breast cancer patients. Specifically, the funding round is expected to allow Concure to double its field sales organization and to focus on training new clinicians nationwide on its Breast Microseed Treatment. Within the last year, the company added to its team several leading breast cancer treatment experts who plan to improve the next-generation device and treatment. “This new financing marks an exciting inflection point for the team at Concure Oncology as well as the patients that we treat, now and moving forward,” said Kevin Kelley, Concure chief financial officer, in a press release. “Combined with the team of experts…
April 17, 2020April 17, 2020